CJC-1295 + Ipamorelin dosing research protocols

“What dose of CJC-1295 and Ipamorelin?” is one of the most-searched questions in the somatotropic-research category — and the honest answer is more specific than the round numbers that circulate online. There is one well-cited human study with actual dose figures, a sharp distinction (the DAC modification) that changes how often the compound is given rather than how much, and a blend format that pairs the two halves. This spoke reports those figures as a research reference and shows the syringe math. It is a research-protocol reference, not a human dosing recommendation.

The honest dosing picture

Unlike many research peptides, CJC-1295 does have a published human dose-ranging study to point at — which makes the temptation to read it as a protocol all the stronger, and all the more mistaken. What the literature contains is a set of single-dose pharmacokinetic figures in healthy volunteers, gathered to characterise the molecule, not to establish a regimen for any purpose. No dose-finding programme advanced to registration, and there is no validated human dose for any unapproved use. The numbers below describe what one study administered to observe an effect; they are not a recommendation.

There is no validated human dose of CJC-1295 or Ipamorelin for any unapproved use. The figures below are the amounts a specific published study administered — they describe an experiment, not an established protocol for people.

This matters because neither compound is an approved medicine. CJC-1295 never advanced past early-phase human pharmacokinetic work under its original sponsor; Ipamorelin reached a phase-2 programme for an unrelated surgical indication that was discontinued. So the “clinical record”, where it exists, is a set of trial doses that did not advance to registration rather than a settled regimen. Everything below is a research reference.

The published CJC-1295 figures

The single most useful dose reference is the 2006 study by Teichman and colleagues in the Journal of Clinical Endocrinology & Metabolism, which administered single subcutaneous doses of CJC-1295 to healthy adults and tracked the hormonal and pharmacokinetic response [1]. The doses were expressed per kilogram of body weight, escalating to roughly 30–60 µg/kg, and were reported as well tolerated across the range studied.

• Dose range — single SC, ~30–60 µg/kg. A single subcutaneous administration in healthy adults, dosed by body weight, escalating to the 30–60 µg/kg region [1]. These are study figures, not a body-weight protocol for any use.
• GH response — dose-dependent, multi-day. Mean growth-hormone levels rose in a dose-dependent fashion and remained elevated for at least six days after a single dose.
• IGF-1 response — sustained 9–11 days. The downstream IGF-1 elevation tracked the GH rise and persisted for roughly 9–11 days, mirroring the molecule’s long circulation.
• Half-life — 5.8–8.1 days. The measured plasma half-life of 5.8–8.1 days is the pharmacokinetic basis for everything in the dosing-frequency section below.
• Tolerability. The single doses across the range were reported as well tolerated in the study population — a safety observation in a small early-phase study, not a clearance for human use.

The through-line: this is one study, single-dose, in healthy volunteers, characterising pharmacokinetics. It establishes that CJC-1295 has a remarkably long hormonal footprint — and that long footprint is exactly what the next section is about.

DAC and dosing frequency

The most consequential thing to understand about CJC-1295 dosing is that the central variable is frequency, not just amount — and frequency is governed entirely by the DAC modification. “CJC-1295 with DAC” (drug-affinity complex) carries a maleimidopropionamide group that covalently binds plasma albumin, extending the half-life into the multi-day range measured by Teichman — 5.8–8.1 days [1]. That long half-life is what makes infrequent administration (for example, weekly in research models) pharmacologically coherent: a single dose keeps GH-releasing-hormone tone elevated for the better part of a week.

The dosing-frequency logic is borne out in the animal record. In GHRH-knockout mice, once-daily CJC-1295 normalised growth-velocity endpoints; when the dosing interval was stretched to every 48–72 hours, the effect became progressively weaker [2]. In other words, the DAC form’s long half-life supports less-frequent dosing than a native peptide would — but there is still a frequency below which the sustained elevation falls off.

• CJC-1295 with DAC (~8-day half-life). Albumin-bound, long-circulating. Supports infrequent administration; the once-daily / less-frequent normalisation work is the direct evidence for this [2].
• Modified GRF(1-29) — “CJC-1295 without DAC” (~30-min half-life). Omits the albumin-binding group and clears in roughly half an hour, so it requires frequent dosing to maintain any sustained GHRH tone. Pharmacologically a different proposition despite the shared name.
• The naming trap. Research-supply listings for “CJC-1295” can mean either form. The DAC vs no-DAC distinction is the first thing to confirm on any certificate of analysis, because it changes the entire frequency picture.

The DAC modification doesn’t change the dose so much as the calendar: with DAC, the ~8-day half-life is what makes infrequent administration coherent; without it, Modified GRF(1-29) clears in ~30 minutes and the frequency question is completely different.

Ipamorelin and the blend

Where CJC-1295 raises the baseline GHRH signal, Ipamorelin supplies the acute pulse. The 1998 foundational study established Ipamorelin as a selective growth-hormone secretagogue that produces potent, dose-dependent GH release without the ACTH and cortisol elevations that limit older secretagogues in research [3]. It is short-acting: its effect is a 30–90 minute GH peak, not a multi-day elevation. That is precisely why the two compounds are studied together.

Researchers therefore frequently study a pre-mixed CJC-1295 + Ipamorelin blend in a single vial: the sustained GHRH-analogue component (CJC-1295) raises baseline tone, and the pulsatile ghrelin-mimetic component (Ipamorelin) supplies the on-demand peak on top of that elevated baseline. The commercial blends pair the two at roughly 1:1 by mass, which is a convention rather than a published dose-response optimum. For the receptor pharmacology behind why the pairing is studied at all, see CJC-1295 + Ipamorelin mechanism research; for how the two compounds differ head-to-head, see CJC-1295 vs Ipamorelin. Ipamorelin is also studied on its own, supplied as Ipamorelin 5 mg.

Reconstitution & the math

Both compounds are lyophilised peptides and reconstitute with standard bacteriostatic water — sterile water containing ~0.9% benzyl alcohol as a preservative — which keeps a multi-dose vial usable across its reconstituted window. The mechanics are the same for the blend as for either compound alone: introduce the diluent slowly down the inside wall of the vial rather than aiming the stream at the powder cake, then swirl gently to dissolve — never shake, which can shear and denature the peptide. Reconstituted material is generally kept refrigerated at 2–8°C and protected from light. The general diluent and documentation framework is in our reconstitution & CoA guide.

Because the published CJC-1295 figures are expressed per kilogram of body weight, any worked example is necessarily arbitrary — the point of the math below is to show how a chosen amount in micrograms maps onto syringe units, not to endorse a target.

Related reading in the cluster

For why the two compounds are paired at the receptor level, see CJC-1295 + Ipamorelin mechanism research. For a head-to-head of the long-acting GHRH analogue against the short-acting secretagogue, see CJC-1295 vs Ipamorelin. For the diluent and documentation framework, see reconstitution & CoA. Overview: CJC-1295 + Ipamorelin synopsis · research peptides in the UAE. Supply: CJC-1295 + Ipamorelin blend research-consultation page · Ipamorelin 5 mg research-consultation page.

Further reading

Peer-reviewed citations used inline:

• [1] Teichman, et al. — J Clin Endocrinol Metab 2006. Single subcutaneous CJC-1295 in healthy adults (doses to ~30–60 µg/kg); dose-dependent GH elevation ≥6 days, IGF-1 elevation 9–11 days, half-life 5.8–8.1 days, well tolerated. DOI 10.1210/jc.2005-1536.
• [2] Alba, et al. — Am J Physiol Endocrinol Metab 2006. Once-daily CJC-1295 normalises growth in GHRH-knockout mice; every-48–72-hour dosing progressively less effective — the dosing-frequency evidence. DOI 10.1152/ajpendo.00201.2006.
• [3] Raun, et al. — Eur J Endocrinol 1998. Ipamorelin, a selective growth-hormone secretagogue — potent dose-dependent GH release without ACTH/cortisol rise. DOI 10.1530/eje.0.1390552.

Last reviewed 12 June 2026. Wellness Labs supplies Ipamorelin 5 mg and CJC-1295 + Ipamorelin blends as research-grade lyophilised powder for non-clinical investigation. Editorial inbox: info@uaewellnesslab.com.